secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2022-10-26T23:59:59+00:00
Accession:  0001048477-22-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q3 revenue up 24% YoY to $505M; VOXZOGO guidance raised to $140-170M
-----------------------------------------------------------------------------

- Total revenues $505.3M (+24% YoY); GAAP net loss narrowed to $6.7M from $36.5M; Non-GAAP income $82.7M.
- VOXZOGO net product revenue $48.3M, with 713 children treated; full-year guidance raised to $140-170M.
- ROCTAVIAN BLA accepted by FDA, PDUFA March 31, 2023; EU commercial launch underway after August 2022 approval.
- KUVAN revenue fell 16% QoQ and 20% YTD due to U.S. generic competition, as expected.
- Full-year total revenue guidance reaffirmed at $2.06-2.16B; R&D and SG&A guidance ranges revised modestly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847722000030/0001048477-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847722000030/bmrn-20221026.htm
  HTML page:      https://secwatch.observer/filing/0001048477-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer